Validation of the Toronto hepatocellular carcinoma risk index for patients with cirrhosis in China: a retrospective cohort study

Validation of the Toronto hepatocellular carcinoma risk index for patients with cirrhosis in China: a retrospective cohort study

Abstract Background The Toronto hepatocellular carcinoma (HCC) risk index (THRI) was developed to predict HCC in patients with cirrhosis. This study aimed to validate the THRI in a 10-year Asian cohort. Methods A total of 2836 patients with cirrhosis at the First Affiliated Hospital of Soochow Unive...

Full description

Bibliographic Details
Main Authors: Huixian Zhang, Jinzhou Zhu, Liting Xi, Chunfang Xu, Airong Wu
Format: Article
Language:English
Published: BMC 2019-04-01
Series:World Journal of Surgical Oncology
Subjects:
Cirrhosis
Hepatocellular carcinoma (HCC)
Toronto hepatocellular carcinoma risk index (THRI)
Validation
Online Access:http://link.springer.com/article/10.1186/s12957-019-1619-3

Internet

http://link.springer.com/article/10.1186/s12957-019-1619-3

Similar Items